← All stories
Markets
HUTCHMED (HCM) Reports Insolvency Proceedings at Former Director Dr Dan Eldar’s Ex-Company S.D. Sight Diagnostics
HUTCHMED (China) Limited (Nasdaq/AIM: HCM; HKEX: 13), a commercial-stage biopharmaceutical firm specializing in oncology and immunology therapies, has issued a regulatory update under AIM Rule 17 Schedule 2(g) revealing insolvency proceedin…
Covered by 1 outlet
All coverage · 1 article